Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1178607

Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker?


Golčić, Marin; Petković, Marija
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker? // Medical Hypotheses, 94 (2016), 148-150 doi:10.1016/j.mehy.2016.07.015 (recenziran, članak, znanstveni)


CROSBI ID: 1178607 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker?

Autori
Golčić, Marin ; Petković, Marija

Izvornik
Medical Hypotheses (0306-9877) 94 (2016); 148-150

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Biomarkers, Tumor ; Carcinoma, Renal Cell ; Ferritins ; Kidney Neoplasms

Sažetak
Metastatic renal cell carcinoma (mRCC) develops in approximately 33% of all renal cancer patients. First line treatment of mRCC includes drugs such as sunitinib, temsirolimus and pazopanib, with overall survival now reaching up to 43, 6 months in patients with favorable-risk metastatic disease. Several side-effects in mRCC treatment, such as hypothyroidism, can be used as positive prognostic factors and indicate good response to therapy. Hypercholesterolemia and hypertriglyceridemia independent of hypothyroidism are reported as side-effects in temsirolimus treatment and recently in sunitinib treatment, but the exact mechanism and significance of the changes remains elusive. Most likely, metabolic changes are caused by inhibition of mechanistic target of rapamycin (mTOR), a positive target of tumor growth suppression, but also a regulator of iron homeostasis. There are no clinical studies reporting changes in iron and ferritin levels during mRCC biotherapy, but we hypothesize that inhibition of mTOR will also affect iron and ferritin levels. If both lipid and iron changes correlate, there is a high possibility that both changes are primarily caused by mTOR inhibition and the level of change should correlate with the inhibition of mTOR pathway and hence the efficacy of targeted treatment. We lastly hypothesize that mRCC biotherapy causes hypercholesterolemia with a possibly improved cholesterol profile due to increase HDL/LDL ratio, so statins might not have a role as supplementary treatment, whereas a sharp rise in triglyceride levels seems to be the primary target for additional therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka

Profili:

Avatar Url Marija Petković (autor)

Poveznice na cjeloviti tekst rada:

doi pubmed.ncbi.nlm.nih.gov

Citiraj ovu publikaciju:

Golčić, Marin; Petković, Marija
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker? // Medical Hypotheses, 94 (2016), 148-150 doi:10.1016/j.mehy.2016.07.015 (recenziran, članak, znanstveni)
Golčić, M. & Petković, M. (2016) Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker?. Medical Hypotheses, 94, 148-150 doi:10.1016/j.mehy.2016.07.015.
@article{article, author = {Gol\v{c}i\'{c}, Marin and Petkovi\'{c}, Marija}, year = {2016}, pages = {148-150}, DOI = {10.1016/j.mehy.2016.07.015}, keywords = {Biomarkers, Tumor, Carcinoma, Renal Cell, Ferritins, Kidney Neoplasms}, journal = {Medical Hypotheses}, doi = {10.1016/j.mehy.2016.07.015}, volume = {94}, issn = {0306-9877}, title = {Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker?}, keyword = {Biomarkers, Tumor, Carcinoma, Renal Cell, Ferritins, Kidney Neoplasms} }
@article{article, author = {Gol\v{c}i\'{c}, Marin and Petkovi\'{c}, Marija}, year = {2016}, pages = {148-150}, DOI = {10.1016/j.mehy.2016.07.015}, keywords = {Biomarkers, Tumor, Carcinoma, Renal Cell, Ferritins, Kidney Neoplasms}, journal = {Medical Hypotheses}, doi = {10.1016/j.mehy.2016.07.015}, volume = {94}, issn = {0306-9877}, title = {Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer – A new potential biomarker?}, keyword = {Biomarkers, Tumor, Carcinoma, Renal Cell, Ferritins, Kidney Neoplasms} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font